The following discussion is an archived discussion of the proposal. Please do not modify it. Subsequent comments should be made in a new section on the talk page. No further edits should be made to this section.
The result of the proposal was moved. --BDD (talk) 17:12, 26 March 2014 (UTC)
2C-E-NBOMe → 25E-NBOMe – The title 2C-E-NBOMe should be changed to the accepted Braden-nomenclature (Mol. Pharmacol. 2006, 70(6), 1956-1964, doi:10.1124/mol.106.028720) which uses the format 25X-NBYYY, where '25' denotes that the two methoxy groups are in the 2 and 5 position, the 'X' is the 4-sustituent usually a halogen, alkyl or thioalkyl group and is named using the same nomenclature as Alexander Shulgin uses in Pihkal for '2C-X' compounds e.g. C for chlorine, D, for methyl, T2 for thioethyl etc. The N-benzyl part of the molecule is described by the 'NBOMe' which means 2-methoxybenzyl, 'NBF' means 2-fluorobenzyl, 'NBOH' means 2-hydroxybenzyl, 'NBMD' means 2,3-methylenedioxybenzyl etc. Other naming schemes include a combination of Shulgin and Braden nomenclature e.g '2C-E-NBOMe' and 'NBOMe-2C-E' both of which are non-canonical and contribute to the confusion between simple phenethylamines such as 2C-E and their N-benzyl counterparts i.e. 25E-NBOMe. Not only is it annoying that articles exist using alternate naming schemes, the use of the non-canonical terms makes it more difficult for users to distinguish between compounds that may be 100 fold more potent and this confusion has led to overdoses in the past. --Relisted.Xoloz (talk) 17:40, 18 March 2014 (UTC) 220.127.116.11 (talk) 09:47, 25 February 2014 (UTC)
The above discussion is preserved as an archive of the proposal. Please do not modify it. Subsequent comments should be made in a new section on this talk page. No further edits should be made to this section.